Benitec Biopharma
From Wikipedia, the free encyclopedia
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997.[1] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.[2]
 | A major contributor to this article appears to have a close connection with its subject. (June 2014) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: BNTC | |
| Industry | RNA interference |
| Founded | 1997 |
| Headquarters | Melbourne, Victoria, Australia |
Key people | Michael Graham (founding scientist & head of discovery) |
| Products | |
| Website | www.benitec.com |
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.[3]
Research and development
Benitec Biopharma is researching ddRNAi in the following fields:
- Hepatitis B (under development with partner Biomics Biotechnologies)[4])
- Oculopharyngeal muscular dystrophy (OPMD)[5][6]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.